vanda pharmaceuticals

Seeking Alpha lists Biotech stocks that are currently very cheap, but are anticipating significant growth in the future. Chelsea Therapeutics (NASDAQ: CHTP) is one to watch, Seeking Alpha explains, “Chelsea Therapeutics (CHTP) is trading around $4. CHTP is a biotechnology company, based in North...

Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) announced that Novartis (NYSE: NVS) has initiated a Phase 1 study “to evaluate a once-monthly injectable microsphere formulation and an aqueous crystals formulation of Fanapt,” Hapoalim Securities reports. “The pharmacokinetic study will likely be a three...

Jefferies, which lowered its PT on shares of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), is providing some color on the stock. “VNDA reported Q4 results with EPS upside on lower R&D as cost was pushed into 2011,” Jefferies writes. “More importantly, Fanapt sales (and royalties to VNDA) should...

Jefferies & Company has lowered the price target on Vanda Pharmaceuticals (NASDAQ: VNDA) from $11 to $10 and maintains its Buy rating.

Hapoalim Securities is lowering its PT on Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) to $15 from $16. “Titan Pharmaceuticals pre-announced 4Q10 Fanapt sales of $5.1 million, which was significantly lower than the $13.2 million we were modeling,” Hapoalim Securities writes. “We now estimate that...

Hapoalim Securities is decreasing its estimates on Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). “Based on current Fanapt prescription trends, we are slightly lowering our revenue estimates for Vanda, which slightly decreases our 2011-2014 EPS estimates,” Hapoalim Securities writes. “Our new 2011-2014...

Hapoalim Securities reports that Vanda Pharmaceuticals (NASDAQ: VNDA) announced that it received a private letter ruling from the IRS stating that Vanda can offset a portion of its taxable income with its full net operating loss carry forwards. “We were previously discounting Vanda's cash position...

Hapoalim Securities has published a research report for Vanda Pharmaceuticals (NASDAQ: VNDA) reiterating its Buy rating. In the report, Hapoalim writes "Fanapt prescriptions for the week of September 24, 2010, were up 17% on a week-over-week basis and at an all time high since the launch. Based on...